Ken Griffin Akouos, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.16 $81,692 - $162,127	-31,420 Reduced 2.28%	1,346,141 $9.1 Million
Q2 2022 Aug 15, 2022	BUY	$2.46 - $5.2 $78,710 - $166,379	31,996 Added 2.38%	1,377,561 $6.46 Million
Q1 2022 May 16, 2022	SELL	$4.16 - $9.08 $45,036 - $98,300	-10,826 Reduced 0.8%	1,345,565 $6.39 Million
Q4 2021 Feb 14, 2022	BUY	$7.65 - $11.38 $50,612 - $75,290	6,616 Added 0.49%	1,356,391 $11.5 Million
Q3 2021 Nov 15, 2021	BUY	$9.93 - $13.59 $10,019 - $13,712	1,009 Added 0.07%	1,349,775 $15.7 Million
Q2 2021 Aug 16, 2021	SELL	$11.87 - $15.96 $30,280 - $40,713	-2,551 Reduced 0.19%	1,348,766 $16.9 Million
Q1 2021 May 17, 2021	SELL	$13.87 - $21.04 $161,391 - $244,821	-11,636 Reduced 0.85%	1,351,317 $18.7 Million
Q4 2020 Feb 16, 2021	BUY	$17.03 - $22.45 $289,629 - $381,807	17,007 Added 1.26%	1,362,953 $27 Million
Q3 2020 Nov 16, 2020	BUY	$19.3 - $26.92 $2.37 Million - $3.31 Million	123,041 Added 10.06%	1,345,946 $30.8 Million
Q2 2020 Aug 14, 2020	BUY	$22.0 - $22.5 $26.9 Million - $27.5 Million	1,222,905 New	1,222,905 $27.5 Million

Ticker AKUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,929,000
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.